SyntheMed REPEL-CV Receives Russian Approval

SyntheMed, a biomaterials company engaged in the development of anti-adhesion products, announced that its REPEL-CV barrier has received approval from the Ministry of Health of the Russian Federation for use in all patients who undergo open heart surgery. The product will be marketed in Russia by...

Sirtris Begins Clinical Trials On Anti-Aging Drug

“Who wants to live forever?” the rock band Queen once sang. If the billions of dollars Americans spend each year on vitamin supplements and cosmetic surgery are any indication, plenty of people would eagerly leap headfirst into the Fountain of Youth if it existed. Now, the New York Times reports...

Jennerex Raises $5.1 Million for Oncology Pipeline

Vaccine company Jennerex has raised $5.1 million in a Series C round of financing. The money will allow Jennerex to continue advancing its pipeline of virus-based oncology products. A second closing is expected on September 15. The San Francisco-based company has not identified its...

OneMedPlace Interviews Jeffrey Davis, CEO of Access Pharmaceuticals

Last month, OneMedPlace reported on MuGard, a preventive oral mucositis treatment from Dallas-based Access Pharmaceuticals (ACCP). MuGard has performed extremely well in post-approval studies, and is poised to break into a $5 billion worldwide market. OneMedPlace recently sat down with Jeffrey Davis,...

FDA Approves Harder-to-Abuse Painkiller Embeda

King Pharmaceuticals announced that the painkiller Embeda has been approved by the U.S. Food and Drug Administration for the management of moderate to severe chronic pain. Embeda is an extended-release opioid drug that is designed to be more difficult for patients to abuse. Patients can induce euphoria by...

Anadys Shares Jump Following Hepatitis C Drug Trial

Shares in Anadys Pharmaceuticals rose 28 percent following the announcement of promising results in a clinical trial of its experimental hepatitis C drug ANA773. The short-term, early-stage study found that ANA773 performed significantly better than a placebo in reducing the severity...

Dendreon to Build $70 Million Plant Near Atlanta

Dendreon Corp. a pharmaceutical company focused on developing cancer treatments, has announced plans to open a $70 million manufacturing plant near Atlanta. The 160,000 square-foot facility could bring at least 300 jobs to Georgia. The announcement ends nearly a month of speculation surrounding the...

New Software Brings Scientists Together

Imagine thousands of scientists across the globe collaborating to find a cure for cancer or create a new malaria vaccine. A new software application from pharmaceutical company  could make this scenario possible, reports Digital Beat. The software, called ChemBioConnect, is the result of a partnership...